Tedizolid phosphate disodium salt

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581141

CAS#: 856867-39-5

Description: Tedizolid phosphate is a novel antibacterial prodrug with potent activity against Gram-positive pathogens. In vitro and in vivo studies demonstrated that the prodrug is rapidly converted by nonspecific phosphatases to the biologically active moiety tedizolid. Tedizolid phosphate is a next-generation oxazolidinone with activity against both methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus spp. Tedizolid has consistently shown potency advantages over linezolid against Gram-positive microorganisms including those with reduced susceptibility to linezolid. Of particular significance, minimum inhibitory concentrations of tedizolid appear to be largely unaffected by the chloramphenicol-florfenicol resistance (cfr) gene, which has been implicated in a number of published linezolid-resistant organism outbreaks.

Chemical Structure

img
Tedizolid phosphate disodium salt
CAS# 856867-39-5
Instruction

Theoretical Analysis

MedKoo Cat#: 581141
Name: Tedizolid phosphate disodium salt
CAS#: 856867-39-5
Chemical Formula: C17H14FN6Na2O6P
Exact Mass: 494.05
Molecular Weight: 494.290
Elemental Analysis: C, 41.31; H, 2.86; F, 3.84; N, 17.00; Na, 9.30; O, 19.42; P, 6.27

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Tedizolid phosphate disodium salt; DA 7218; TR 701; Torezolid phosphate sodium salt; TR-701;

IUPAC/Chemical Name: 2-Oxazolidinone, 3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl)phenyl)-5-((phosphonooxy)methyl)-, disodium salt, (5R)-

InChi Key: UAIJRGWLKLRQAH-CURYUGHLSA-L

InChi Code: InChI=1S/C17H16FN6O6P.2Na/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(30-17(24)25)9-29-31(26,27)28;;/h2-7,12H,8-9H2,1H3,(H2,26,27,28);;/q;2*+1/p-2/t12-;;/m1../s1

SMILES Code: O=C1O[C@@H](COP([O-])([O-])=O)CN1C2=CC=C(C3=CC=C(C4=NN(C)N=N4)N=C3)C(F)=C2.[Na+].[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 494.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013 Feb 13;309(6):559-69. doi: 10.1001/jama.2013.241. PubMed PMID: 23403680.

2: Chan LC, Basuino L, Dip EC, Chambers HF. Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2015;59(6):3252-6. doi: 10.1128/AAC.04376-14. Epub 2015 Mar 23. PubMed PMID: 25801564; PubMed Central PMCID: PMC4432129.

3: O'Riordan W, Green S, Mehra P, De Anda C, Fang E, Prokocimer P. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary. Clin Infect Dis. 2014 Jan;58 Suppl 1:S43-50. doi: 10.1093/cid/cit617. Review. PubMed PMID: 24343832.

4: Gras J. Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections. Drugs Today (Barc). 2014 Nov;50(11):729-37. doi: 10.1358/dot.2014.50.11.2233783. Review. PubMed PMID: 25525633.

5: Kennedy G, Osborn J, Flanagan S, Alsayed N, Bertolami S. Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube Administration. Drugs R D. 2015 Dec;15(4):329-33. doi: 10.1007/s40268-015-0108-6. PubMed PMID: 26416654; PubMed Central PMCID: PMC4662946.

6: Ong V, Flanagan S, Fang E, Dreskin HJ, Locke JB, Bartizal K, Prokocimer P. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos. 2014 Aug;42(8):1275-84. doi: 10.1124/dmd.113.056697. Epub 2014 May 29. PubMed PMID: 24875463.

7: Das D, Tulkens PM, Mehra P, Fang E, Prokocimer P. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary. Clin Infect Dis. 2014 Jan;58 Suppl 1:S51-7. doi: 10.1093/cid/cit618. Review. PubMed PMID: 24343833.

8: Rybak JM, Roberts K. Tedizolid Phosphate: a Next-Generation Oxazolidinone. Infect Dis Ther. 2015 Feb 24. [Epub ahead of print] PubMed PMID: 25708156; PubMed Central PMCID: PMC4363212.

9: Hall RG 2nd, Michaels HN. Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections. Infect Drug Resist. 2015 Apr 22;8:75-82. doi: 10.2147/IDR.S56691. eCollection 2015. Review. PubMed PMID: 25960671; PubMed Central PMCID: PMC4411017.

10: Urbina O, Ferrández O, Espona M, Salas E, Ferrández I, Grau S. Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections. Drug Des Devel Ther. 2013 Apr 3;7:243-65. doi: 10.2147/DDDT.S30728. Print 2013. Review. PubMed PMID: 23589680; PubMed Central PMCID: PMC3622392.

11: Choi S, Im W, Bartizal K. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae. Antimicrob Agents Chemother. 2012 Sep;56(9):4713-7. doi: 10.1128/AAC.00346-12. Epub 2012 Jun 19. PubMed PMID: 22713339; PubMed Central PMCID: PMC3421900.

12: Hussar DA, Nguyen A. Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab. J Am Pharm Assoc (2003). 2014 Nov-Dec;54(6):658-62. doi: 10.1331/JAPhA.2014.14543. PubMed PMID: 25379985.

13: Flanagan S, Minassian SL, Morris D, Ponnuraj R, Marbury TC, Alcorn HW, Fang E, Prokocimer P. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother. 2014 Nov;58(11):6471-6. doi: 10.1128/AAC.03431-14. Epub 2014 Aug 18. PubMed PMID: 25136024; PubMed Central PMCID: PMC4249404.

14: Lodise TP, Drusano GL. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate. Clin Infect Dis. 2014 Jan;58 Suppl 1:S28-34. doi: 10.1093/cid/cit615. Review. PubMed PMID: 24343829.

15: Burdette SD, Trotman R. Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic. Clin Infect Dis. 2015 Oct 15;61(8):1315-21. doi: 10.1093/cid/civ501. Epub 2015 Jun 23. Review. PubMed PMID: 26105167.

16: Ghazi I, Hamada Y, Nicolau DP. Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration. Am J Health Syst Pharm. 2016 Nov 1;73(21):1769-1776. PubMed PMID: 27769972.

17: Cada DJ, Ingram K, Baker DE. Tedizolid phosphate. Hosp Pharm. 2014 Nov;49(10):961-71. doi: 10.1310/hpj4910-961. PubMed PMID: 25477569; PubMed Central PMCID: PMC4252220.

18: Wong E, Rab S. Tedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infections. P T. 2014 Aug;39(8):555-79. PubMed PMID: 25136252; PubMed Central PMCID: PMC4123804.

19: Flanagan S, Fang E, Muñoz KA, Minassian SL, Prokocimer PG. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy. 2014 Sep;34(9):891-900. doi: 10.1002/phar.1458. Epub 2014 Jul 3. PubMed PMID: 24989138; PubMed Central PMCID: PMC4260119.

20: Molina-Torres CA, Barba-Marines A, Valles-Guerra O, Ocampo-Candiani J, Cavazos-Rocha N, Pucci MJ, Castro-Garza J, Vera-Cabrera L. Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages. Ann Clin Microbiol Antimicrob. 2014 Apr 4;13:13. doi: 10.1186/1476-0711-13-13. PubMed PMID: 24708819; PubMed Central PMCID: PMC3986449.